Posts Tagged ‘cancer risk’
Joe Elia • December 3rd, 2010
This week’s guest, Dr. Sripal Bangalore, finds no evidence that use of the standard anti-hypertensive drugs increases risks for cancer. His meta-analysis did find, however, an indication that ARBs and ACE inhibitors, when used in combination, increase risks modestly. Even with the short follow-up, Bangalore says clinicians should find reassurance in the results. Listen [...]
Joe Elia • November 2nd, 2010
OK, now what can be done to control hypertension among African American men? What about recruiting barbershops to put a shoulder to the wheel? They’re community centers, trusted sources of gossip and advice, and places of relaxation. In Texas, a group of researchers undertook a randomized trial in black-owned barbershops in which barbers took [...]
Joe Elia • October 8th, 2010
We welcome Dr. Danielle Bowen Scheurer to our conversational team this week She’s a hospitalist at the Medical University of South Carolina and an associate editor of Physician’s First Watch. Our guest is Dr. Deepak Bhatt, who has just published some reassuring results on omeprazole’s putative interaction with clopidogrel in the New England Journal [...]
Joe Elia • June 18th, 2010
A JAMA paper suggests that in all but the most severe exacerbations of COPD, it’s best to start off with low-dose oral corticosteroids rather than the higher-dose intravenous treatment that, contrary to guideline recommendations, almost everyone now gets. Our conversation this week is with the study’s first author, Dr. Peter Lindenauer. Visit the Journal [...]
Joe Elia • April 9th, 2010
Repetitive tasks, like making sure to wash your hands after seeing each patient, may seem like drudgery, but they save patients’ lives. This week we talk with Prof. Elizabeth Robb and Sir Brian Jarman about their success at chopping hospital mortality rates with simple checklists. Sir Brian has offered to monitor your hospital’s stats [...]
Joe Elia • July 2nd, 2009
Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what [...]
